Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection

Pedro Romero-Aroca,1 Laura Sararols,2 Lluis Arias,3 Ricardo P Casaroli-Marano,4 Francisca Bassaganyas51Department of Ophthalmology, Hospital Universitari Sant Joan, Universidad Rovira i Virgili, Reus, 2Department of Ophthalmology, Hospital de Granollers, Granollers, 3Department of Ophthalmology, Hos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Romero-Aroca P, Sararols L, Arias L, Casaroli-Marano RP, Bassaganyas F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f8c013e3713d47cbb7b43a00bcfac4c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8c013e3713d47cbb7b43a00bcfac4c2
record_format	dspace
spelling	oai:doaj.org-article:f8c013e3713d47cbb7b43a00bcfac4c22021-12-02T06:33:11ZTopical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection1177-54671177-5483https://doaj.org/article/f8c013e3713d47cbb7b43a00bcfac4c22012-10-01T00:00:00Zhttp://www.dovepress.com/topical-azithromycin-or-ofloxacin-for-endophthalmitis-prophylaxis-afte-a11214https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Pedro Romero-Aroca,1 Laura Sararols,2 Lluis Arias,3 Ricardo P Casaroli-Marano,4 Francisca Bassaganyas51Department of Ophthalmology, Hospital Universitari Sant Joan, Universidad Rovira i Virgili, Reus, 2Department of Ophthalmology, Hospital de Granollers, Granollers, 3Department of Ophthalmology, Hospital Universitari de Bellvitge, Barcelona, 4Instituto Cl&iacute;nico de Oftalmologia, Hospital Cl&iacute;nic de Barcelona, Barcelona, 5Department of Ophthalmology, Hospital de la Sant Creu i Sant Pau, Barcelona, SpainBackground: The number of patients who have undergone intravitreal injections has increased enormously in recent years, but a consensus is still lacking on prophylaxis for endophthalmitis. The aim of this prospective, observational study was to evaluate the prophylactic effect of azithromycin eye drops versus ofloxacin eye drops.Methods: The study was conducted in five hospitals in Spain and included all patients undergoing intravitreal injections of triamcinolone, bevacizumab, ranibizumab, or pegaptanib over one year. Patients received azithromycin 15 mg/g eye drops (twice daily on the day prior to injection and for another 2 days) or ofloxacin 3 mg/g eye drops (every 6 hours on the day prior to injection and for another 7 days).Results: In the azithromycin group, there were 4045 injections in 972 eyes of 701 patients. In the ofloxacin group, there were 4151 injections in 944 eyes of 682 patients. There were two cases of endophthalmitis (0.049%) in the azithromycin group and five (0.12%) in the ofloxacin group. The odds ratio of presenting with endophthalmitis in the ofloxacin group compared with the azithromycin group was 2.37 (95% confidence interval [CI] 1.32&ndash;3.72, P &lt; 0.001). There were two cases of noninfectious uveitis after triamcinolone injection in the azithromycin group (0.049%) and two (0.048%) in the ofloxacin group; no significant differences were observed (odds ratio 0.902, 95% CI 0.622&ndash;1.407, P = 0.407). Conjunctival hyperemia was observed in 12 cases in the azithromycin group and none in the ofloxacin group.Conclusion: The risk of endophthalmitis was significantly greater with ofloxacin than with azithromycin. These findings provide a valuable addition to the ever-increasing pool of information on endophthalmitis prophylaxis after intravitreal injection, although further large-scale studies are required to provide definitive conclusions.Keywords: endophthalmitis prophylaxis, intravitreal injections, azithromycin, ofloxacin, antibioticsRomero-Aroca PSararols LArias LCasaroli-Marano RPBassaganyas FDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1595-1599 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Romero-Aroca P Sararols L Arias L Casaroli-Marano RP Bassaganyas F Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
description	Pedro Romero-Aroca,1 Laura Sararols,2 Lluis Arias,3 Ricardo P Casaroli-Marano,4 Francisca Bassaganyas51Department of Ophthalmology, Hospital Universitari Sant Joan, Universidad Rovira i Virgili, Reus, 2Department of Ophthalmology, Hospital de Granollers, Granollers, 3Department of Ophthalmology, Hospital Universitari de Bellvitge, Barcelona, 4Instituto Cl&iacute;nico de Oftalmologia, Hospital Cl&iacute;nic de Barcelona, Barcelona, 5Department of Ophthalmology, Hospital de la Sant Creu i Sant Pau, Barcelona, SpainBackground: The number of patients who have undergone intravitreal injections has increased enormously in recent years, but a consensus is still lacking on prophylaxis for endophthalmitis. The aim of this prospective, observational study was to evaluate the prophylactic effect of azithromycin eye drops versus ofloxacin eye drops.Methods: The study was conducted in five hospitals in Spain and included all patients undergoing intravitreal injections of triamcinolone, bevacizumab, ranibizumab, or pegaptanib over one year. Patients received azithromycin 15 mg/g eye drops (twice daily on the day prior to injection and for another 2 days) or ofloxacin 3 mg/g eye drops (every 6 hours on the day prior to injection and for another 7 days).Results: In the azithromycin group, there were 4045 injections in 972 eyes of 701 patients. In the ofloxacin group, there were 4151 injections in 944 eyes of 682 patients. There were two cases of endophthalmitis (0.049%) in the azithromycin group and five (0.12%) in the ofloxacin group. The odds ratio of presenting with endophthalmitis in the ofloxacin group compared with the azithromycin group was 2.37 (95% confidence interval [CI] 1.32&ndash;3.72, P &lt; 0.001). There were two cases of noninfectious uveitis after triamcinolone injection in the azithromycin group (0.049%) and two (0.048%) in the ofloxacin group; no significant differences were observed (odds ratio 0.902, 95% CI 0.622&ndash;1.407, P = 0.407). Conjunctival hyperemia was observed in 12 cases in the azithromycin group and none in the ofloxacin group.Conclusion: The risk of endophthalmitis was significantly greater with ofloxacin than with azithromycin. These findings provide a valuable addition to the ever-increasing pool of information on endophthalmitis prophylaxis after intravitreal injection, although further large-scale studies are required to provide definitive conclusions.Keywords: endophthalmitis prophylaxis, intravitreal injections, azithromycin, ofloxacin, antibiotics
format	article
author	Romero-Aroca P Sararols L Arias L Casaroli-Marano RP Bassaganyas F
author_facet	Romero-Aroca P Sararols L Arias L Casaroli-Marano RP Bassaganyas F
author_sort	Romero-Aroca P
title	Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
title_short	Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
title_full	Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
title_fullStr	Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
title_full_unstemmed	Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
title_sort	topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/f8c013e3713d47cbb7b43a00bcfac4c2
work_keys_str_mv	AT romeroarocap topicalazithromycinorofloxacinforendophthalmitisprophylaxisafterintravitrealinjection AT sararolsl topicalazithromycinorofloxacinforendophthalmitisprophylaxisafterintravitrealinjection AT ariasl topicalazithromycinorofloxacinforendophthalmitisprophylaxisafterintravitrealinjection AT casarolimaranorp topicalazithromycinorofloxacinforendophthalmitisprophylaxisafterintravitrealinjection AT bassaganyasf topicalazithromycinorofloxacinforendophthalmitisprophylaxisafterintravitrealinjection
_version_	1718399911308820480

Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection

Ejemplares similares